Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India

CONCLUSION: Using intermediate-dose prophylactic factor VIII therapy is a cost-effective approach that improves clinical outcomes compared to on-demand therapy in the Indian adult and pediatric HA populations without inhibitors.PMID:37933875 | DOI:10.1080/16078454.2023.2277497

Source: Hematology - November 7, 2023 Category: Hematology Authors: Tulika Seth Kapil Garg Prakas Kumar Mandal Anupam Datta Shailendra Verma Suresh Hanagavadi Usha Rani Thota Source Type: research